A direct trial with a different purpose
SURPASS-2 randomized 1,879 adults with type 2 diabetes to three tirzepatide target doses or semaglutide 1 mg weekly for 40 weeks. Treatment assignment was open-label. The primary endpoint was change in glycated hemoglobin, or HbA1c, rather than weight. Eli Lilly funded the study. [1]
The semaglutide dose and primary outcome are essential to an honest comparison. Calling this simply tirzepatide versus semaglutide leaves out the information needed to know which clinical question it answers. Direct randomization is valuable, but it does not make all possible formulations and regimens equivalent to the ones tested.
Glucose and weight findings
HbA1c fell by 2.01, 2.24 and 2.30 percentage points with tirzepatide, versus 1.86 with semaglutide. Weight reduction favored tirzepatide by 1.9, 3.6 and 5.5 kg, respectively. Gastrointestinal events were the most common adverse events in both treatment groups and were generally mild or moderate. [1]
The weight figures here are between-group differences in kilograms, not the total percentage of body weight lost. A chart that relabels them or blends them with percentages from another trial misstates the evidence. Units and comparison direction need to remain visible next to every numerical claim.
Why SURMOUNT-5 is a separate article
Our SURMOUNT-5 analysis addresses the later obesity-focused head-to-head study on its own terms. It should not be merged with SURPASS-2 as though the participants, regimens and main research question were identical.
An open-label design also deserves explicit mention. Participants and investigators knew which active treatment was assigned. This does not cancel randomization, but it matters when considering treatment experience and participation. The most reliable consumer summary describes that feature without either dismissing the study or pretending it was fully masked.
A reduction in HbA1c is also expressed in percentage points, rather than a percentage of the starting HbA1c. That unit can be easy to overlook when the same article discusses weight. Keep glucose percentages, weight percentages and kilograms in distinct columns when taking notes.
Use the comparison that fits the conversation
If the immediate question is diabetes management, ask the clinician how this glucose-focused comparison relates to the broader plan. If the question is weight management without diabetes, begin with research addressing that population. Choosing the appropriate question first is more useful than searching for whichever trial has the largest apparent advantage.
For help separating endpoints and comparators, use our trial-reading guide. Provider choice remains a different exercise involving follow-up, access and cost. Neither this direct drug comparison nor a later one can establish which company communicates best or offers the most appropriate ongoing care for an individual.